Physician profile
Miriam M Jackson
NPI 1588905541
$2,131.07
in general payments reported to CMS, 2019-2025
27 companies · $804 in 2025
The $804 reported for 2025 was more than what 96% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $222 · 2023: $676 · 2024: $430 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,909.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $538.31 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $432.33 | 2023-2025 | |
| Ucb, INC. | $355.11 | 2022-2025 | Fintepla, Briviact, Nayzilam |
| Nobelpharma America, LLC | $83.51 | 2024 | |
| Vertical Pharmaceuticals, LLC | $74.06 | 2024-2025 | Relexxii |
| Otter Pharmaceuticals, LLC | $72.66 | 2025 | Sympazan |
| Upsher-Smith Laboratories LLC | $71.03 | 2024-2025 | |
| Noven Therapeutics, LLC | $62.14 | 2024-2025 | Xelstrym |
| Corium, LLC | $40.16 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $39.86 | 2023-2024 | Jornay Pm |
| Immedica Pharma US, INC. | $31.72 | 2023 | |
| Neurelis, INC. | $30.57 | 2023 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $29.30 | 2025 | Elaprase |
| Biogen, INC. | $28.96 | 2025 | Skyclarys |
| Intrabio INC | $26.72 | 2025 | Aqneursa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $23.65 | 2023 | Dyanavel Xr |
| Ptc Therapeutics, INC. | $23.00 | 2022 | |
| Itamar Medical INC | $21.21 | 2023 | Watchpatone |
| Catalyst Pharmaceuticals, INC. | $19.39 | 2025 | |
| Eisai INC. | $19.00 | 2023 | |
| Pyros Pharmaceuticals, INC. | $18.32 | 2023 | Vigpoder |
| Collegium Pharmaceutical, INC. | $16.15 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $15.85 | 2024 | Adzenys Xr-Odt |
| Alexion Pharmaceuticals, INC. | $15.46 | 2025 | Strensiq |
| Aucta Pharmaceuticals, INC. | $14.92 | 2025 | Motpoly Xr |
| Avion Pharmaceuticals | $14.21 | 2023 | Methylphenidate Hydrochloride |
| Genentech USA, INC. | $13.47 | 2024 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miriam Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.